Expression of oncofetal antigen glypican-3 associates significantly with poor prognosis in HBV-related hepatocellular carcinoma
Metrics: PDF 975 views | HTML 1252 views | ?
Li Wang1,2,*, Liuhong Pan1,*, Min Yao3,*, Yin Cai1, Zhizhen Dong4, Dengfu Yao1
1Research Center of Clinical Medicine, Affiliated Hospital of Nantong University, Nantong 226001, China
2Department of Medical Informatics, Medical School of Nantong University, Nantong 226001, China
3Department of Immunology, Medical School of Nantong University, Nantong 226001, China
4Department of Diagnostics, Affiliated Hospital of Nantong University, Nantong 226001, China
*These authors contributed equally to this work
Dengfu Yao, email: firstname.lastname@example.org
Keywords: hepatocellular carcinoma, glypican-3, prognosis, tissue microarrays, immunohistochemistry
Received: April 18, 2016 Accepted: May 23, 2016 Published: June 07, 2016
Hepatocellular carcinoma (HCC) is one of the most common malignancies worldwide with poor prognosis. However, its prognostic evaluation is still an urgent problem. The objectives of this present study were to investigate oncofetal antigen glypican-3 (GPC-3) expression in HCC and their match para-cancerous tissues by the array technology with immunohistochemistry and estimate its value as a novel prognostic marker for HCC. The incidence of GPC-3 expression was 95.7 % in the cancerous tissues with significantly higher (χ2 = 33.824, P < 0.001) than that in the para-cancerous tissues (52.2 %). Abnormal expression of GPC-3 in HCC tissues was markedly related to poor or moderate differentiation (P < 0.001), hepatitis B virus (HBV) infection (P = 0.004), periportal cancer embolus (P = 0.043), and tumor-node- metastasis staging (P = 0.038). According to the univariate and multivariate analysis, the overall survival of HCC patients with high GPC-3 level was significantly worse than those with low or without GPC-3 expression (P < 0.001), suggesting that abnormal GPC-3 expression should be an independent prognostic factor for HBV-related HCC patient’s survival.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.